Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23925541 | 0.88 | GOT1 (0.79) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23925546 | 0.86 | GOT1 (0.75) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL734585 | 0.84 | MEN1 (1.00) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12655245 | 0.84 | GOT1 (0.72) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL30578783 | 0.83 | MAPT (0.75) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL18485914 | 0.79 | GOT1 (0.64) | GOT1MEN1KMT2AALOX15POLB | |
| SCHEMBL23925545 | 0.78 | MAPT (0.76) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23925504 | 0.78 | GOT1 (0.78) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23925548 | 0.77 | TSHR (0.68) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL11546329 | 0.77 | ADRA2A (0.63) | GOT1MEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | claimed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | claimed |
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | GOT1 871/4885MEN1 2778/4885KMT2A 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.